Mar. 12 at 6:58 PM
$CLRB 💪
💪💪💪💪💪💪A second-line approval for Iopofosine I-131 would double the addressable market to approximately 11,500 patients, positioning it as the primary solution for those failing BTKi therapies. With potential orphan drug pricing between
$150,000 and
$300,000 per patient, the drug could achieve peak annual sales of
$250M to
$400M in the U.S. alone.
🚀🚀🚀🚀🚀🚀
